Retrovirology

Table 2 Percent Inhibition of HIV Replication

From: Antigen-presenting particle technology using inactivated surface-engineered viruses: induction of immune responses against infectious agents

			Particle Preparations
Expt.	Infecting Virus	Inhibition Index	Virus	Modification	Time Points (days)					Donor
					6	14
1.	HIV-MN	0	HIV-1	non-engineered	0	0				M
		55		B7-engineered	70	40
		95		B7+antiCD3	94	95
		0	HSV-2	B7+antiCD3	0	0
	HIV-Ba-L	0	HIV-1	non-engineered	0	0
		71		B7-engineered	82	60
		94		B7+antiCD3	90	98
		0	HSV-2	B7+antiCD3	0	0
					6	17
2.	HIV-MN	80	HIV-1	B7-engineered	70	89				N
		88		B7+antiCD3	88	89
		0	HHV-8	B7+antiCD3	0	0
					4	11	14
3.	HIV-MN	96	HIV-1	B7-engineered	92	98	99			O
		55		B7+antiCD3	56	45	63
					3	7	12	17
4.	HIV-MN	0	HIV-1	non-engineered	0	0	0	0		J
		86		B7-engineered	55	91	99	99
		59		B7+antiCD3	46	67	51	73
	HIV-Ba-L	0	HIV-1	non-engineered	0	0	0	0
		90		B7-engineered	60	98	100	100
		88		B7+antiCD3	72	97	99	84
					4	6	9	12
5.	HIV-MN	89	HIV-1	B7-engineered	65	97	98	97		P
		75		B7+antiCD3	73	96	82	48
					4	6	9	12	17
6.	HIV-MN moi = 1	85	HIV-1	B7-engineered	57	80	96	96	94	P
		76		B7+antiCD3	59	82	90	90	59
	HIV-MN moi = 2	74	HIV-1	B7-engineered	33	95	75	75	94
		79		B7+antiCD3	40	92	85	85	95
	HIV-MN moi = 4	52	HIV-1	B7-engineered	55	97	35	35	40
		38		B7+antiCD3	60	54	36	36	2
	HIV-MN moi = 8	40	HIV-1	B7-engineered	53	60	0	0	8
		28		B7+antiCD3	37	60	20	20	2

Back to article page

ISSN: 1742-4690

Contact us

Submission enquiries: journalsubmissions@springernature.com